No qualifying author-owned investment thesis was confirmed in this post.
The author explicitly states 'No position' and frames the analysis as a research-worthy watch rather than a directional investment thesis.
Score18
Comments26
▶ Full Post Text
TDOC isn't one turnaround story. It's two businesses stapled together. One looks like boring infrastructure. The other is shrinking fast. The market is pricing the whole thing like it's mostly the second one.
I work in clinical operations (20 years) and started reading Teladoc's SEC filings when they began acquiring companies that touch real clinical workflows. Here's what the filings show.
**Company A: Integrated Care (B2B)**
Revenue $389.5M in Q3 2025, up 2% YoY. Adjusted EBITDA margin: 17%. U.S. membership: 102.5M (up from 91.8M YoY). Enterprise virtual care: urgent care, chronic care (Livongo), expert opinions, B2B mental health. Per-member-per-month economics. Sticky contracts. Real clinical infrastructure.
**Company B: BetterHelp (DTC therapy)**
Revenue $236.9M in Q3 2025, down 8% YoY. Adjusted EBITDA margin: 1.6%. Paying users \~380k and declining. CAC is still high. It's a consumer subscription business under pressure.
**Combined:** TTM revenue \~$2.53B. Net loss through first 9 months of 2025: \~$175M. Market cap: \~$860M. That valuation reflects \~$1.4B in debt/convertibles, shrinking BetterHelp, ongoing losses, and execution risk on the insurance pivot.
**The Livongo deal**
Acquired for $18.5B in Oct 2020. Total goodwill write-downs now exceed $14B since 2022. Most of Livongo's senior leadership left within a year. Chronic care enrollment missed expectations for multiple quarters. Stock: $308 peak → under $5 today. \~98% down.
**BetterHelp: unit economics problem, not PR**
Topped $1B revenue in 2022, declined every quarter since. Paying users: \~415k (Q1 2024) → \~388k (Q2 2025). Management chose margin over growth, but margins are still thin (\~1.6% EBITDA). Feb 2025 Blue Orca short report alleged quality/AI issues; Teladoc denied. FTC settled for $7.8M in 2023 over health data sharing with ad platforms. Whether the allegations hold or not, trust is the product here, and the overhang is real.
**The insurance pivot = execution risk**
Teladoc is moving BetterHelp from cash-pay to insurance. Bought UpLift for $30M, rolling out in several states, targeting broader coverage in 2026. Per-session revenue will be lower. BetterHelp's 30k+ therapists are mostly 1099 contractors. Credentialing them across payers and states takes months per provider. Many joined specifically for the cash-pay model. They're changing the engine while losing altitude.
**Inside signals:** Glassdoor 3.1, CFO departed Oct 2025, employee reviews point to ongoing layoffs/reorgs. Leadership churn during a pivot is execution risk.
**What actually works**
Strip out BetterHelp and Integrated Care is a \~$1.5B revenue B2B healthcare company with mid-teens margins and real infrastructure. Not exciting. But real.
**What would change my mind**
More bullish if: BetterHelp stabilizes paying users for two consecutive quarters. Insurance conversion improves segment margins. Integrated Care growth accelerates.
More bearish if: Integrated Care EBITDA drops below \~15%. BetterHelp cash burn accelerates. Another major impairment hits.
Next earnings: Feb 25, 2026. Street consensus: Hold, median target \~$8.75. Current price: \~$5.
Sources: SEC filings, IR releases, public FTC documents. No position. Not investment advice. Happy to discuss.